ReviewPediatric transplantation2026
Intestinal and Multivisceral Transplantation: Where We Stand Today.
Review in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intestinal and Multivisceral Transplantation: Where We Stand Today.Pediatric transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal and multivisceral transplantation has evolved from an experimental to a life-saving procedure for children and adults with complications of gut failure (GF). Suboptimal long-term outcomes of transplant elicit recent advances in surgical and medical gut rehabilitation along with the introduction of glucagon-like peptide-2 (GLP-2) that has established a new paradigm achieving nutritional autonomy reserving transplantation for rescue. Notably, continued improvement of transplant has been observed over the last decade. The 2025 International Intestinal Transplant Registry (IITR) report demonstrates continued era-based improvement, with overall 5-year patient survival of 60% and graft survival of 51% for pediatric recipients, and 52% and 46%, respectively, for adult recipients. Over 90% of long-term transplant survivors achieve full nutritional autonomy. Contemporary cohorts show substantially better outcomes, reflecting advances in surgical technique and immunosuppression. Key developments include refined indications, sophisticated surgical techniques for complex anatomy, and updated immunosuppressive protocols. The integration of composite tissue transplantation, particularly abdominal wall allografts, vascularized and non-vascularized rectus sheath fascia has addressed closure challenges. Despite advances in transplantation, chronic rejection remains the primary barrier to long-term graft survival. Future directions include technological innovations in organ preservation, machine perfusion and organoid transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.